In some tumor types, namely lung, kidney, and breast tumors, the event of SMARCA2 downregulation occurs during cancer de-differentiation (disease progression), suggesting a clonal selection of SMARCA2-abrogated cancer cells [127,128,129,130]. This evidence concerns the gene SMARCA2 and breast neoplasm.